Mirae Asset Global Etfs Holdings Ltd. Avidity Biosciences, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.4 Billion
- Q1 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 143,805 shares of RNA stock, worth $4.77 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
143,805
Previous 144,570
0.53%
Holding current value
$4.77 Million
Previous $4.2 Million
0.98%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding RNA
# of Institutions
244Shares Held
116MCall Options Held
289KPut Options Held
998K-
Janus Henderson Group PLC London, X011.4MShares$379 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.3MShares$376 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$321 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.24MShares$307 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.75MShares$290 Million4.23% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.73B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...